Welcome to our dedicated page for Viatris Ord Shs SEC filings (Ticker: VTRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viatris Inc. (Nasdaq: VTRS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand how Viatris reports its financial performance, governance decisions and key corporate events as a global healthcare company that bridges generics and brands.
Viatris regularly files current reports on Form 8‑K to announce material events such as quarterly financial results, changes to bylaws, board appointments and other significant corporate actions. For example, the company has used Form 8‑K to report results for periods ended June 30 and September 30, 2025, and to disclose amendments to its bylaws related to proxy access and annual meeting timing. These filings often reference accompanying press releases that provide additional detail.
The company’s proxy statement on Schedule 14A (DEF 14A) offers insight into governance, board composition, executive compensation and strategic priorities. In its definitive proxy statement, Viatris discusses its enterprise-wide strategic review, capital return plans, pipeline progress and long-term shift toward a greater share of innovative brands, giving shareholders context for voting decisions and for evaluating management’s plans.
On this page, users can also monitor other SEC forms that may appear over time, such as annual and quarterly reports or any insider transaction reports on Form 4, as they become available. Stock Titan enhances these filings with AI-powered summaries that highlight key points, explain technical language and help readers quickly identify topics such as revenue trends, strategic initiatives, bylaw changes and risk factors relevant to Viatris’ pharmaceutical preparation manufacturing business.
Filings are updated as they are released through EDGAR, allowing investors, analysts and other stakeholders to follow how Viatris communicates its financial condition, governance framework and strategic evolution through official regulatory channels.
Viatris Inc. announced a planned Chief Financial Officer transition. Theodora “Doretta” Mistras will step down as CFO effective May 8, 2026, remaining employed until May 22, 2026 to support the handover, and her departure is stated as unrelated to any disagreements over accounting, financial reporting, internal controls or operations.
The Board appointed Paul Campbell, the current Chief Accounting Officer and Corporate Controller, as interim CFO effective May 8, 2026 while it searches for a permanent successor. Mistras will receive a pro rata 2026 bonus based on actual performance (capped at target) but no severance or equity vesting, and must sign a release and comply with restrictive covenants. Viatris also reiterated that it will release first‑quarter 2026 results on May 7, 2026 and hold a conference call at 8:30 a.m. ET.
Viatris Inc reports institutional ownership disclosure: Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 84,807,083 shares of Viatris common stock, representing 7.36% of the class as of 03/31/2026. The filing shows sole dispositive power over 84,807,083 shares and sole voting power over 10,090,452 shares. The filing states these holdings reflect securities managed across Vanguard affiliates and funds. Signature on the form is dated 04/30/2026.
Viatris Inc Chief Commercial Officer Corinne Le Goff reported routine equity compensation activity tied to previously granted awards. On April 15, 2026, 39,344 restricted stock units and 3,643.8335 related dividend equivalent units vested and were converted into the same number of common shares.
The company withheld 19,067 common shares at $13.86 per share to cover associated tax liabilities, a non-market, tax-withholding disposition rather than an open-market sale. After these transactions, Le Goff holds 107,135 shares of Viatris common stock directly.
Viatris Inc. presents its 2026 proxy statement and notice of annual meeting, combining a performance review with key voting items for shareholders. In 2025 the company generated $14.3 billion in total revenues, returned more than $1 billion to shareholders via dividends and buybacks, and completed 60 regional business development transactions, including acquiring Aculys Pharma in Japan.
The proxy highlights five positive Phase 3 data readouts, a pipeline that includes selatogrel and cenerimod, and a global footprint delivering more than 70 billion doses of medicine across over 165 countries and territories in 2025. It also describes an enterprise‑wide strategic review aimed at optimizing structure, resource allocation and efficiency to support long‑term growth.
Shareholders are asked to elect 13 directors, approve on a non‑binding basis 2025 compensation for named executive officers, and ratify Deloitte & Touche LLP as auditor for 2026. Governance themes include an independent Chair, 12 of 13 director nominees classified as independent, formation of a Strategic Review Committee, and continued board refreshment, with seven new directors appointed since December 2022. The filing notes strong shareholder engagement and that the 2025 Say‑on‑Pay proposal received approximately 95% support.
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting 0% ownership of Viatris Inc. Common Stock as of the amendment. The filing explains an internal realignment effective January 12, 2026 that disaggregated certain subsidiaries and business divisions from The Vanguard Group, Inc., and states those entities will report beneficial ownership separately.
The Schedule indicates Amount beneficially owned: 0 and sole and shared voting and dispositive powers: 0. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Viatris Inc officer Paul Campbell reported an open-market sale of 21,350 shares of common stock at a weighted average price of $13.2805 per share. After this sale, he directly holds 366,288 shares, plus 318 shares held indirectly through a 401(k) plan, indicating he retains a substantial position.
Viatris Inc Chief Commercial Officer Corinne Le Goff reported equity compensation activity centered on restricted stock units and related tax withholding. On March 6, 2026, 44,165 RSUs granted on March 6, 2025 vested and were settled into an equal number of Viatris common shares, along with 2,193 dividend equivalent units that also converted into common stock. To cover tax liabilities on these vestings, 20,561 common shares were withheld at $14.16 per share instead of being retained.
Le Goff also received a new grant of 88,984 RSUs, each representing one future share of common stock. According to the vesting schedule, 29,662 of these RSUs are scheduled to vest on March 6, 2027, and 29,661 are scheduled to vest on each of March 6, 2028 and March 6, 2029, while 44,164 RSUs from the 2025 grant remain scheduled to vest on March 6, 2027 and March 6, 2028. Following these transactions, Le Goff directly holds 83,214 shares of Viatris common stock.
Viatris Inc Chief Financial Officer Theodora Mistras reported several equity-compensation transactions. On March 6, 2026, 41,711 restricted stock units (RSUs) granted on March 6, 2025 vested and were settled into common shares, along with 2,070.6039 related dividend equivalent units (DEUs).
To cover tax obligations on these vestings, 23,067 and 1,146 common shares were withheld at $14.16 per share, so there was no open‑market sale. She also received a new grant of 86,017 RSUs that convert one‑for‑one into Viatris common stock.
Following these transactions, Mistras directly held 70,645 common shares, plus 86,017 RSUs and 4,141 DEUs. The new RSU grant vests in three annual installments: 28,673 units on March 6, 2027 and 28,672 units on each of March 6, 2028 and March 6, 2029.